AKTS
Aktis Oncology, Inc. Common stockNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage limited
$16.64-4.04%
Close Oct 13, 2026
- Market cap
- $920.51M
- 1 month
- -28.2%
- 3 months
- -36.0%
- 1 year
- —
- Dividend
- No dividends on record
- Next-quarter EPS estimate
- -$0.46Quarter to Sep 30, 2026 · 7 analysts · revenue $2.33M
- Short interest
- 16.5% of float4.7M shares · settled Sep 30, 2026 · +45.0% since Sep 15, 2026 · FINRA
Fundamentals · trailing 12 months to Jun 30, 2026
- Revenue
- $10.06M
- Net income
- -$73.14M
- Free cash flow
- -$84.57M
- Book value
- $484.84M
- Total debt
- $11.24M
- P/E
- —
- Price / sales
- 91.5×
- Price / book
- 1.9×
- FCF yield
- -9.2%
- Net margin
- -727.0%
EODHD (TTM) · as of Oct 13, 2026
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if AKTS is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
28 top institutions tracked
as of 2026-Q2 (filed 2026-09-22)
Last 13F trend: accumulating (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: bearish
Last trade: sell 20 days ago
Red flags: 0
Largest 13-F holders · Q2 2026
114 filers reported a long position in AKTS for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| MPM BioImpact LLC | $155.9M | 4.8M | Unchanged |
| EcoR1 Capital, LLC | $155.5M | 4.8M | Unchanged |
| Blue Owl Capital Holdings LP | $99M | 3.1M | -2.9% |
| BlackRock, Inc. | $73.4M | 2.3M | +7.9% |
| T. Rowe Price Investment Management, Inc. | $66.1M | 2.1M | -3.4% |
| WELLINGTON MANAGEMENT GROUP LLP | $63.4M | 2M | -15.1% |
| RTW INVESTMENTS, LP | $51.3M | 1.6M | Unchanged |
| RA CAPITAL MANAGEMENT, L.P. | $42.4M | 1.3M | -12.6% |
| Jupiter Topco LLC | $42.4M | 1.3M | — |
| BAKER BROS. ADVISORS LP | $32.1M | 996.4K | Unchanged |
Get the Full Analysis for AKTS
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.